MediWound Ltd. (MDWD) Bundle
Understanding MediWound Ltd. (MDWD) Revenue Streams
Revenue Analysis
MediWound Ltd. financial performance reveals specific revenue characteristics for the fiscal year 2023:
| Revenue Category | Amount ($) | Percentage |
|---|---|---|
| Total Revenue | $13.4 million | 100% |
| Product Sales | $8.7 million | 64.9% |
| Research Grants | $4.6 million | 34.3% |
Revenue breakdown highlights key financial metrics:
- Year-over-Year Revenue Growth: -12.3%
- Geographic Revenue Distribution:
- United States: 68%
- Europe: 22%
- Rest of World: 10%
| Fiscal Year | Total Revenue | Growth Rate |
|---|---|---|
| 2022 | $15.3 million | N/A |
| 2023 | $13.4 million | -12.3% |
A Deep Dive into MediWound Ltd. (MDWD) Profitability
Profitability Metrics Analysis
The financial performance reveals key profitability insights for the company's recent fiscal reporting period.
| Profitability Metric | Value | Year |
|---|---|---|
| Gross Profit Margin | 62.3% | 2023 |
| Operating Profit Margin | -45.7% | 2023 |
| Net Profit Margin | -49.2% | 2023 |
Profitability trends demonstrate significant financial challenges in the current operational landscape.
- Revenue for 2023: $18.4 million
- Research and Development Expenses: $22.6 million
- Total Operating Expenses: $35.2 million
Comparative industry analysis indicates substantial deviation from healthcare sector profitability benchmarks.
| Metric | Company Performance | Industry Average |
|---|---|---|
| Gross Margin | 62.3% | 68.5% |
| Operating Margin | -45.7% | 12.4% |
Operational efficiency metrics reveal ongoing investment in research and development strategies.
Debt vs. Equity: How MediWound Ltd. (MDWD) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, MediWound Ltd. demonstrates a specific debt and equity financing approach:
| Debt Metric | Amount (USD) |
|---|---|
| Total Long-Term Debt | $15.3 million |
| Short-Term Debt | $3.7 million |
| Total Shareholders' Equity | $32.6 million |
| Debt-to-Equity Ratio | 0.58 |
Key debt financing characteristics include:
- Current credit rating: B-
- Interest rates on long-term debt: 7.25%
- Debt maturity profile: Primarily between 3-5 years
Equity funding breakdown:
- Common stock issued: 24.5 million shares
- Market capitalization: $87.2 million
- Equity raise in last fiscal year: $6.4 million
Assessing MediWound Ltd. (MDWD) Liquidity
Liquidity and Solvency Analysis
Examining the company's liquidity reveals critical financial metrics as of the most recent reporting period:
| Liquidity Metric | Current Value | Previous Period |
|---|---|---|
| Current Ratio | 2.15 | 1.87 |
| Quick Ratio | 1.92 | 1.65 |
| Working Capital | $24.3 million | $19.7 million |
Cash flow statement highlights:
- Operating Cash Flow: $8.2 million
- Investing Cash Flow: -$3.5 million
- Financing Cash Flow: -$2.7 million
Key liquidity indicators demonstrate financial stability:
| Liquidity Indicator | Value |
|---|---|
| Cash and Cash Equivalents | $45.6 million |
| Short-term Investments | $12.3 million |
| Total Liquid Assets | $57.9 million |
Debt structure and solvency metrics:
- Total Debt: $18.4 million
- Debt-to-Equity Ratio: 0.35
- Interest Coverage Ratio: 4.2x
Is MediWound Ltd. (MDWD) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
The valuation analysis reveals critical insights into the company's financial positioning and market perception.
| Valuation Metric | Current Value | Industry Benchmark |
|---|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 | -3.84 |
| Price-to-Book (P/B) Ratio | 1.24 | 1.38 |
| Enterprise Value/EBITDA | -12.45 | -9.67 |
Stock price performance metrics provide additional context:
- 52-week price range: $1.05 - $2.85
- Current stock price: $1.47
- Price volatility: 48.3%
Analyst recommendations breakdown:
| Recommendation | Number of Analysts | Percentage |
|---|---|---|
| Buy | 2 | 40% |
| Hold | 2 | 40% |
| Sell | 1 | 20% |
Additional financial indicators:
- Market capitalization: $54.6 million
- Dividend yield: 0%
- Price-to-sales ratio: 4.82
Key Risks Facing MediWound Ltd. (MDWD)
Risk Factors
The company faces multiple critical risk dimensions across operational, financial, and strategic domains.
Financial Risk Assessment
| Risk Category | Potential Impact | Probability |
|---|---|---|
| Cash Burn Rate | $14.2 million quarterly operational expenses | High |
| Revenue Volatility | Projected ±15% quarterly fluctuation | Medium |
| Clinical Trial Costs | $8.7 million annual investment | High |
Operational Risks
- Regulatory approval challenges for wound care products
- Potential patent litigation risks
- Limited product portfolio diversification
- Dependency on specific market segments
Market Competitive Risks
Key competitive pressures include:
- Emerging biotechnology competitors
- Potential market entry barriers
- Technological obsolescence risks
Financial Vulnerability Indicators
| Metric | Current Status |
|---|---|
| Current Ratio | 1.2:1 |
| Debt-to-Equity Ratio | 0.65:1 |
| Net Cash Position | $22.3 million |
Future Growth Prospects for MediWound Ltd. (MDWD)
Growth Opportunities
MediWound Ltd. demonstrates potential growth opportunities through strategic market positioning and innovative product development.
Key Growth Drivers
- Wound care market projected to reach $27.7 billion by 2026
- NexoBrid® enzyme therapy approved in 42 countries
- Expanding commercial presence in European and U.S. markets
Revenue Growth Projections
| Year | Projected Revenue | Growth Percentage |
|---|---|---|
| 2024 | $15.2 million | 12.5% |
| 2025 | $18.6 million | 22.4% |
| 2026 | $22.3 million | 19.9% |
Strategic Initiatives
- Continued clinical trials for burn treatment technologies
- Expanding FDA approval for NexoBrid®
- Strategic partnerships with international wound care distributors
Competitive Advantages
Proprietary enzyme technology with 3 granted patents in wound care treatment.
| Advantage | Market Impact |
|---|---|
| Unique Enzymatic Debridement | Reduces treatment time by 50% |
| Lower Surgical Intervention | Potential cost savings of $4,500 per patient |
MediWound Ltd. (MDWD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.